The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics, Therapeutics), Application ...

The data indicated that the leading drug demonstrated superior cancer cell killing in contrast to Xtandi (enzalutamide) and ...

Lantheus Holdings offers a compelling bull case, with PYLARIFY and DEFINITY driving valuation and strong growth prospects.

The firm hopes to overcome common dose-limiting toxicities with its PSMA-targeted radiotherapy while boosting potency versus competitors.

Broker UBS believes the three-year rout of ASX healthcare stocks is near an end and it has promoted Cochlear and Resmed to favourite stocks.

JPM's strong NII outlook, NVS's blockbuster pipeline, and T's wireless momentum anchor today's top analyst picks.

Common isotopes include lutetium-177, actinium-225, gallium-68 (diagnostic), fluorine-18, and radium-223. The therapy combines isotopic radiance with molecular targeting-e.g., PSMA in prostate cancer ...

Illuccix® (kit for the preparation of gallium-68 ( 68 Ga) gozetotide injection), Telix's first generation PSMA-PET imaging ...

Northwell’s Phelps Hospital is the first and only medical facility in New York State between the Bronx and Albany to offer Pluvicto, a groundbreaking treatment for men with advanced prostate cancer.

The Trump administration is weighing measures that would make it more expensive for pharmaceutical companies to conduct ...

Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and patent dispute, saying the law firm wrongly switched sides despite a conflict.

Montreal, QC [June 18, 2025] – Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib tablets) in combination with an aromatase ...